Week Ending Friday, November 20, 2026
U.S. stocks finished a turbulent week with a sharp Friday selloff as concerns about artificial intelligence valuations, infrastructure financing and policy uncertainty overwhelmed an improvement in consumer confidence. The Nasdaq Composite dropped 5.28% in the final session, the S&P 500 fell 3.70%, and the Dow Jones Industrial Average lost 949.73 points, or 1.93%. The disconnect between the economy and the stock market stood out. Households reported better expectations for business conditions and some relief from gasoline prices, while equity markets confronted a more immediate question: whether the enormous sums flowing into AI can generate returns that justify both valuations and financing costs. Anthropic (ANT), Nvidia (NVDA) and SpaceX (SPCX) were central to that debate.
Friday’s Closing Market Performance
| Index or indicator | Closing level | Friday change | Friday percentage change |
|---|---|---|---|
| S&P 500 | 6,910.39 | −265.44 | −3.70% |
| Dow Jones Industrial Average | 48,147.33 | −949.73 | −1.93% |
| Nasdaq Composite | 22,617.73 | −1,261.47 | −5.28% |
| Russell 2000 | 2,581.79 | −73.32 | −2.76% |
| VIX | 35.89 | +7.45 | +26.04% |
The selloff extended beyond large technology stocks. The Russell 2000’s 2.76% decline showed that smaller companies also faced selling pressure, while the VIX’s jump to 35.89 underscored the deterioration in market sentiment. The Dow held up better than the Nasdaq, but its nearly 950-point decline left little room to describe the session as a simple rotation between sectors.
Treasury Yields, Commodities and Bitcoin
| Asset or benchmark | Supplied closing snapshot | Change |
|---|---|---|
| U.S. 10-year Treasury yield | 4.912% | −0.140 percentage point |
| December 2026 crude oil futures | $83.73 per barrel | +$1.29, or +1.56% |
| Gold | $3,518.00 per ounce | −$167.50, or −4.54% |
| Bitcoin | $58,565.21 | −$2,904.17, or −4.72% |
The 10-year Treasury yield fell 14 basis points, contrasting with steep declines in equities, gold and bitcoin. That combination suggests a more complicated defensive shift than a broad rush into every asset commonly associated with protection. Crude oil moved in the opposite direction, gaining 1.56% despite the equity market’s weakness. Exact full-week index returns are not included because the supplied screenshots show Friday’s changes rather than week-over-week performance. Earlier market updates had already placed the major indexes on course for substantial weekly losses, but those intraday estimates should not be mistaken for final weekly figures.
What Drove the Week’s Stock Market Selloff?
Anthropic’s IPO Did Not Restore Confidence Across AI
Anthropic (ANT) entered public trading Thursday at $111.50 per share after pricing its initial public offering at $83. The stock subsequently surrendered much of its initial premium, and Friday’s decline became a focal point for a broader reassessment of AI-related risk. The significance extended beyond one newly listed company. A highly anticipated offering can demonstrate demand for a particular business without validating the prices of every company connected to the same theme. This week, enthusiasm for Anthropic (ANT) at its debut coexisted with selling in semiconductor and infrastructure shares. Nvidia (NVDA), Advanced Micro Devices (AMD) and Broadcom (AVGO) were among the chipmakers under pressure in Friday’s trading. Those developments reinforced the market’s increasingly selective treatment of the AI supply chain rather than a uniform assumption that all participants would benefit equally. The individual stock moves reported in the linked live coverage were intraday observations, not verified closing returns.
Hedging Costs Added Another Layer of Uncertainty
Options on Anthropic (ANT) were expected to begin trading Monday, November 23. Before that anticipated launch, market makers were discussing potential implied volatility of approximately 100% to 150%, based on the stock’s early price swings. Those were preliminary estimates rather than established option prices. For many, the practical issue was the cost of protection. Buying a newly public stock during volatile trading is one decision. Finding an affordable way to hedge that exposure is another. The expected options launch could improve access to hedging, but it would not necessarily make protection inexpensive.
Macroeconomic Report: Consumer Confidence Improved, but the Recovery Remained Uneven
The University of Michigan’s final November Consumer Sentiment Index rose to 51.5, up from 48.0 in October. The Current Economic Conditions Index increased to 49.4 from 46.7, while the Expectations Index climbed to 52.9 from 48.8. The university attributed the improvement partly to stronger expectations for business conditions following the midterm elections and relief from declining gasoline prices. Short-term expected business conditions improved 13% from October, while longer-term expectations increased 6%. There were important limits to the rebound:
- Sentiment remained 9% below February’s level.
- Middle- and lower-wealth households reported improving personal finances, while those with the largest stockholdings reported deterioration.
- The 3.5-point monthly increase in the headline index was smaller than the university’s stated 4.8-point threshold for statistical significance at the 95% confidence level.
That last distinction matters. November’s results pointed toward better sentiment, but they did not establish an unambiguous acceleration in household confidence.
Inflation Expectations Eased, but That Is Not the Same as Lower Reported Inflation
Friday’s survey coverage showed one-year inflation expectations declining to 3.7%, from 4.7% a month earlier, while the five-year outlook slipped to 3.3%. These figures describe what consumers expect prices to do, not the measured rate of inflation in government price indexes. The macroeconomic message was therefore mixed but constructive. Easing inflation expectations and lower gasoline prices can support household purchasing confidence. However, subdued sentiment and market volatility still argue against treating the report as an all-clear signal for consumer spending or corporate earnings. The survey also helps explain why improving economic headlines did not stop Friday’s selloff. Its interviews ended November 16, meaning it did not capture the full effect of the week’s final trading sessions or Anthropic’s (ANT) public-market debut.
AI Infrastructure: Financing Costs and Policy Risk Take Center Stage
SpaceX’s $32 Billion Bond Sale Highlights the Price of AI Expansion
SpaceX (SPCX) sold $32 billion of bonds to finance AI-chip purchases, according to Bloomberg. The offering formed part of a broader financing package exceeding $40 billion and involved equipment that the company would lease through a special-purpose structure. The largest bond tranche, approximately $25.2 billion, carried a yield of 8.259%. Bloomberg compared that with an average U.S. high-grade corporate bond yield of 5.95% on Thursday. The financing was tied to purchases of Nvidia (NVDA) equipment, with the broader package intended to fund approximately $47.3 billion of GPU equipment. The transaction illustrated both the availability of capital and its rising complexity. AI infrastructure can attract enormous funding commitments, but lenders still demand compensation for structural risk, equipment lifecycles and uncertainty over future returns. Strong demand for computing capacity does not eliminate the cost of financing it.
Data-Center Tax Threat Introduces a New Policy Question
President Donald Trump said Friday that U.S. companies could face restrictions or a substantial tax penalty for building data centers abroad. The remarks represented a policy threat, not a fully detailed implementation framework in the supplied reporting. The issue matters for multinational cloud and technology companies, including Alphabet (GOOGL), Amazon (AMZN), Microsoft (MSFT), Meta Platforms (META) and Oracle (ORCL), which operate overseas data centers. International facilities can support proximity to customers and compliance with local requirements, making potential restrictions more consequential than a straightforward shift in construction spending. For many, the uncertainty is now twofold: how much AI infrastructure will ultimately earn, and how government policy could change where that infrastructure can be built.
Company Developments Beyond the Index Declines
Apple’s AI-Agent Push Adds Competitive Pressure
Apple (AAPL) drew attention after a job listing described work on an AI agent capable of using a computer, navigating applications and performing multistep tasks. The listing was subsequently removed, according to reporting that cited Bloomberg’s coverage. The competitive implication is that the AI market remains unsettled. Apple’s (AAPL) potential expansion into more capable agents could create another challenge for existing AI platforms, but the listing itself did not constitute a product launch or establish future revenue. It was evidence of development activity, not a completed commercial offering.
Zscaler and CrowdStrike Deal Report Creates a Cybersecurity Exception
Zscaler (ZS) shares jumped approximately 20% following a report that CrowdStrike (CRWD) was in talks to acquire the cybersecurity company. The reported move was associated with acquisition speculation and should not be treated as a verified regular-session closing return.The distinction between talks and an agreement is equally important. The supplied report described discussions, not a completed transaction with confirmed terms. Even so, the development offered a company-specific counterpoint to the broader technology selloff.
Take-Two’s GTA VI Launch Shows the Power of a Major Entertainment Franchise
Take-Two Interactive (TTWO) reported an extraordinary launch for Grand Theft Auto VI. Its Rockstar Games subsidiary said the title generated $3.79 billion in first-day retail sales, with 32.5 million units sold in the pre-release period. Retail sales should not be confused with revenue recognized in Take-Two Interactive’s (TTWO) financial statements. Nevertheless, the launch demonstrated substantial consumer demand for a major entertainment release even as broader market sentiment weakened. The longer-term business question is how that initial demand translates into recurring spending, including online play and subsequent platform releases. The launch establishes a large audience, but the durability and profitability of that audience will matter well beyond opening-week sales,
Gap’s Results Reveal a Divided Apparel Consumer
Gap (GAP) reported fiscal third-quarter revenue of $4.01 billion and adjusted earnings of $0.82 per share. Comparable sales were flat overall, with meaningful differences among its brands. The namesake Gap brand recorded 9% comparable-sales growth, Old Navy’s comparable sales were flat, and Athleta’s comparable sales declined 15%. The company lowered its full-year net-sales outlook to roughly flat and reduced its adjusted earnings guidance to $2.29 to $2.34 per share. Gap (GAP) also named Ashley Kechter to lead Athleta, effective December 14. Its results illustrated why a single conclusion about “the consumer” can be misleading: brand positioning, merchandise execution and weather sensitivity produced sharply different outcomes within the same company.
Kymera Sets Up a Clinical Catalyst for Monday
Kymera Therapeutics (KYMR) announced plans to release results from its BROADEN2 Phase 2b trial of KT-621 in moderate-to-severe atopic dermatitis on Monday, November 23. The company scheduled the results release for 7 a.m. Eastern, followed by a webcast at 8 a.m. Eastern. KT-621 is an investigational oral STAT6 degrader designed to target a pathway involved in Type 2 inflammation. Friday’s announcement established the timing of the readout. It did not disclose efficacy or safety results from the Phase 2b study.
What Matters Next for Markets?
The next phase of trading will test whether company-specific developments can regain influence after a week dominated by broad concerns about AI valuations and funding. Several issues deserve particular attention:
- Anthropic’s (ANT) expected options debut, including the cost and availability of hedging.
- Whether semiconductor shares stabilize after the pressure on Nvidia (NVDA), Advanced Micro Devices (AMD) and Broadcom (AVGO).
- Any formal details behind the proposed restrictions or tax penalties on overseas data-center construction.
- Whether improving household sentiment translates into stronger holiday demand, particularly after Gap’s (GAP) reduced outlook.
- Kymera Therapeutics’ (KYMR) scheduled clinical results, a company-specific catalyst separate from the broader AI trade.
The central tension heading into the next week is not whether AI remains economically important. It is whether the prices, financing structures and spending commitments attached to that opportunity leave enough room for uncertainty. Friday’s closing performance showed how quickly that distinction can matter across the wider market.
Updates From the VP Watchlist
Amwell® (NYSE: AMWL)
Amwell® (NYSE: AMWL), a leading provider of technology-enabled care, closed at $10.75. Amwell reported after the close Nov. 3 the company’s Third Quarter 2026 Highlights: Recorded Total Revenue of $49.0 million, exceeding the previously provided financial guidance range for Q3, Achieved subscription revenue of $23.9 million, Recorded Amwell Medical Group (“AMG”) visit revenue of $23.7 million, Reported gross margin of 53%, Net loss was ($11.0) million, compared to ($9.6) million in the second quarter of 2026, Adjusted EBITDA of ($3.6) million compared to ($1.2) million in the second quarter of 2026, & Total visits on the platform were 0.8 million. Financial Outlook: The Company is raising its 2026 revenue outlook, and adjusted EBITDA outlook, and reaffirming its AMG visit guidance., Revenue in the range of $204 million to $206 million increased from $200 million to $205 million. AMG visits between 1.32 million and 1.37 million Adjusted EBITDA in the range between ($8) million to ($7) million increased from ($9) million to ($7) million.
The Company also provided financial guidance for Q4 2026 Revenue and adjusted EBITDA:
- Q4 revenue in the range of $48 million to $50 million
- Q4 adjusted EBITDA expected to in the range of $0 million to $1 million.
The Company also reiterated its objective to achieve positive cash flow from operations in the fourth quarter of 2026.
Serina Therapeutics (NYSE: SER)
Serina Theraeuptics (NYSE: SER, $1.12) is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina’s POZ PlatformTM provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology.
On Thursday, November 12, Serina reported its financial results for the third quarter ended September 30, 2026, along with key business updates. Steve Ledger, Chief Executive Officer of Serina stated, “We are excited about the achievement of important clinical milestones for SER-252 in Parkinson’s disease, advancing from the initial evaluation of our lowest-dose cohort into the next stage of dose escalation. Importantly, the blinded pharmacokinetic observations from Cohort 1 showed the sustained drug exposure SER-252 was designed to achieve, and the independent Safety Monitoring Committee recommended proceeding with continued development. Dosing in Cohort 2 is currently underway and focuses on demonstrating SER-252’s potential as a differentiated treatment option for patients with advanced Parkinson’s disease to improve the significant challenge of consistent symptom control.”
On Thursday, September 24, 2026, Serina CEO Steve Ledger discussed discuss Serina’s programs’ progress during Tribe Public’s “A New Approach to Advanced Parkinson’s Disease: Serina Discusses SER-252’s Clinical Progress”webinar, followed by a live Q&A. You may view it below.
Eupraxia Pharmaceuticals Inc. (EPRX)
Eupraxia Pharmaceuticals Inc. (EPRX, $5.80), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today, ( Nov. 10), announced its financial results for the third quarter of 2026. Dr. James A. Helliwell, Chief Executive Officer of Eupraxia stated, “We remain on track to report interim results from the Phase 2b portion of the RESOLVE trial in December, and were pleased to announce in mid-October that we had reached our target enrollment of 120 patients. We are very encouraged by the Phase 1b/2a data from the open-label portion of the RESOLVE trial that was reported this quarter, which includes 36- and 52-week data from our highest dosing cohorts. We believe this data provides further evidence of the observed durable treatment effects of EP-104GI in EoE patients, seen in previous cohorts. In total, we have observed 64% of patients remaining in clinical remission over this 52-week period in addition to clinically meaningful histologic improvements. With cash runway into the second half of 2028, we believe we remain well funded to execute on our upcoming milestones for our EoE program.”
EPRX gained a significant new Wall Street endorsement Monday as RBC Capital Markets initiated coverage with an Outperform rating, a Speculative Risk designation and a $14 price target. The research makes a bullish case for EP-104GI, the company’s investigational treatment for eosinophilic esophagitis, ahead of an expected December clinical readout. Against the $6.89 reference price in RBC’s report, the target implies approximately 103% upside, not a forecast of where shares must trade. The attraction is unusually straightforward for biotechnology: take a familiar anti-inflammatory medicine, deliver it precisely into diseased tissue and attempt to make its benefits last long enough to change the treatment routine. If that approach succeeds, Eupraxia would offer more than another prescription for a chronic disease. It could offer a different calendar. RBC analyst Douglas Miehm’s November 9 initiation argues that EP-104GI could occupy a differentiated position in eosinophilic esophagitis, commonly called EoE, through localized delivery and the potential for once-yearly administration. The next major test is whether encouraging early results translate into convincing evidence against a vehicle control in the Phase 2b RESOLVE study.
EPRX announced (Oct. 15) that the ongoing RESOLVE study evaluating the safety and efficacy of EP-104GI for the treatment of Eosinophilic Esophagitis (“EoE”) has reached its enrollment target. “This is a significant milestone for the RESOLVE trial and the development of EP-104GI as a potential treatment option in EoE” said Dr. James Helliwell, Chief Executive Officer of Eupraxia. “We look forward to our interim analysis in December where we will be reporting on symptoms, histologic findings and safety in the first 60 patients in Phase 2b to reach 6 months. Data will also be available on the patients at 3, 9- and 12-month timepoints giving a fulsome interim look at the RESOLVE Trial”.
Modular Medical, Inc. (NASDAQ: MODD)
Modular Medical, Inc. (NASDAQ: MODD, $1.68), a commercial-stage medical device company preparing for the full commercial launch of its next-generation Pivot™ tubeless patch pump, is pursuing a different proposition: make insulin delivery less demanding for the people who must manage it every day. On November 19, Modular Medical announced that it has entered into agreements with the remaining two of the nation’s three largest pharmacy benefit managers (“PBMs”) for its Pivot tubeless patch pump. With these agreements, Modular Medical has now entered into agreements with all three of the nation’s largest PBMs, whose networks collectively cover more than 182 million lives and process approximately 80% of U.S. prescription claims.1 Coverage for any individual patient remains subject to the formulary decisions and benefit design of the applicable health plan or plan sponsor.
New patient research announced November 9 gives that strategy a persuasive commercial foundation. In a three-phase study conducted with Thrivable involving more than 540 people with Type 1 or Type 2 diabetes, approximately nine out of 10 surveyed multiple daily injection users said they would consider a simpler insulin delivery option. In the final-phase survey of 303 participants, 48.5% expressed strong interest in the company’s Pivot tubeless patch pump. The distinction matters. General enthusiasm for something easier is not the same as product-specific interest, and neither is a prescription. Still, the findings suggest Modular Medical is addressing a recognizable problem rather than inventing one for the benefit of a presentation deck. For many following MODD, the emerging opportunity centers on one word: simplicity. The company has already moved beyond the purely developmental stage. Its annual report documents U.S. Food and Drug Administration clearance for Pivot in April 2026, followed by commercial availability and initial patient shipments in June. The question now is whether a differentiated product, improving access and more focused patient education can turn that regulatory foundation into a repeatable commercial business.
MODD announced (Oct. 27) that it has received a positive decision from its notified body regarding certification of its quality management system under ISO 13485:2016. The notified body is designated under the European Union Medical Device Regulation (“MDR”).
Alphabet (NASDAQ: GOOGL $265.29)
Alphabet (NASDAQ: GOOGL, GOOG) is confronting an expensive paradox: Artificial intelligence is bringing more activity to Google while making the economics of that activity harder to predict. Yet the latest results offer a more constructive interpretation than a simple obituary for search. Third-quarter revenue increased 25% to $127.6 billion. Operating income climbed 30% to $40.6 billion. Google Cloud revenue more than doubled. Those are unusual credentials for a company supposedly being escorted toward technological irrelevance. At the close on Thursday, Alphabet shares traded at $283.82, following a 12.64% decline, many are clearly demanding more proof and fewer architectural renderings of future data centers. That skepticism is understandable. But the opportunity lies in distinguishing a difficult transition in monetization from a collapse in demand. Google’s problem is not that people have stopped asking questions. According to management, its year-over-year search-query growth reached its highest rate in five years during the third quarter. The more consequential question is how quickly Google can turn its expanding AI audience into attractive, durable cash flow. Wall Street has little patience for a renovation when the contractor’s estimate begins with a trillion.
Space Exploration Technologies Corp. (SPCX, $127.79)
SpaceX-related coverage is orbiting three themes: a possible combination with Tesla, an expanding AI infrastructure footprint, and robust Starlink demand, because apparently conquering one industry at a time is inefficient. Reported third-quarter revenue totaled $14.6 billion, while management projected first-quarter 2027 revenue of $33 billion–$37 billion, a range with little apparent interest in remaining earthbound.
The Sources
- November 20 stock-market coverage: AI shares, semiconductor weakness and Anthropic’s public debut.
- November 20 market updates: consumer inflation expectations and weekly market context.
- University of Michigan: Sentiment ticks up as election expected to usher in changes to economic policy.
- Bloomberg: SpaceX Sells $32 Billion of AI Chip Debt at Yields Topping 8%.
- Proposed restrictions and tax penalties on overseas data-center construction.
- Anthropic’s share-price volatility and expected options-market debut.
- Apple’s reported AI-agent development efforts.
- Reported acquisition discussions involving Zscaler and CrowdStrike.
- Take-Two’s Grand Theft Auto VI launch and first-day retail sales.
- Gap’s fiscal third-quarter results, revised guidance and Athleta leadership appointment.
- Kymera Therapeutics company release: KT-621 BROADEN2 results scheduled for November 23, 2026.
Stay Updated with Vista Partners
Subscribe to receive market insights, investing ideas, and the latest updates directly in your inbox.
